NCT05613361 is a Phase 3 clinical trial of Colistin in Acute Kidney Injury, sponsored by October 6 University.

Who is sponsoring NCT05613361?

NCT05613361 is sponsored by October 6 University.

What drugs are being tested in NCT05613361?

Interventions in NCT05613361: Colistin, Curcumin.

What condition does NCT05613361 study?

NCT05613361 studies Acute Kidney Injury, Drug-Induced Nephropathy.

Is NCT05613361 still recruiting?

NCT05613361 is currently status unknown. Last updated 31 October 2023.

Last reviewed 2023-10-31 · How we verify

NCT05613361

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Curcumin Against Colistin-induced Nephrotoxicity

Status unknown Phase 3 Last updated 31 October 2023

What this trial tests

Phase 3 trial testing Colistin in Acute Kidney Injury in 214 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
30 April 2024

30 October 2024

Quick facts

Lead sponsor	October 6 University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	214
Start date	1 January 2023
Primary completion	30 April 2024
Estimated completion	30 October 2024
Sites	1 location across Egypt

Drugs / interventions tested

Colistin (COLISTIN) — full drug profile →
Curcumin (CURCUMIN) — full drug profile →

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →
Drug-Induced Nephropathy — all drugs for Drug-Induced Nephropathy →

Sponsor

October 6 University

Who can join

Adults 18 to 65, any sex, with Acute Kidney Injury or Drug-Induced Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to investigate the possible nephroprotective effect of curcumin in critically ill patients receiving colistin.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment.
Yang X, Liu Y, Cao J, Wu C, et al · · 2025 · cited 42× · PMID 40258841 · DOI 10.1038/s41420-025-02491-z
Antimicrobial peptides: from discovery to developmental applications.
Zhang Q. · · 2025 · cited 20× · PMID 40178173 · DOI 10.1128/aem.02115-24
Effect of Cellular Senescence in Disease Progression and Transplantation: Immune Cells and Solid Organs.
Kirchner VA, Badshah JS, Hong SK, Martinez O, et al · · 2024 · cited 8× · PMID 37953486 · DOI 10.1097/tp.0000000000004838
Molecular mechanisms and therapeutic interventions in acute kidney injury: a literature review.
He J, Chen Y, Li Y, Feng Y. · · 2025 · cited 5× · PMID 40121405 · DOI 10.1186/s12882-025-04077-4

Verify or expand the search:

Other trials of Colistin

Trials testing the same drug.

NCT07326540 — Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients W · Phase 3 · not yet recruiting
NCT05586815 — Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection · Phase 4 · unknown
NCT05542446 — Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation · Phase 4 · terminated
NCT05258851 — Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections · Phase 3 · terminated
NCT05689229 — Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Co · Phase 3 · completed

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Other October 6 University trials

Trials by the same sponsor.

NCT07235072 — Passive Fit and Time Efficiency in All On-X Implants Protocols Using Photogrammetry, Splinted Scan Bodies, and Conventio · NA · not yet recruiting
NCT07403851 — Effect of Scanning Technology on the Accuracy of Digitally Customized Intraradicular Attachments · NA · not yet recruiting
NCT07305792 — High Tone Power Therapy on Lumbosacral Radiculopathy Patients · NA · completed
NCT07132736 — Impact of Underwater Exercise Versus Regular Aerobic Exercise on Quality of Life and Power of Muscle · NA · recruiting
NCT07350655 — Efficacy of Virtual Reality-based Training in Patients With Chronic Non-specific Low Back Pain · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05613361 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by October 6 University
Last refreshed: 31 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05613361.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing